Literature DB >> 24035906

Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells.

Yuchen Liu1, Hongzhou Cui, Wenjun Wang, Longnian Li, Zaixing Wang, Sen Yang, Xuejun Zhang.   

Abstract

microRNA sponges antagonizing the oncogenic microRNAs are potential candidates for RNA-based cancer therapies. Although the constructed sponges so far are to some extent suitable for biological experiments, they can only express at relative low levels in cells, because they are sensitive to microRNA-mediated activation of deadenylation and subsequent exonucleolytic degradation. Since circular RNA molecules are resistant to exonuclease degradation, we report the production of circular microRNA sponges against miR-21 or miR-221 in cell lines using the self-splicing permuted intron-exon sequences derived from T4 bacteriophage gene td. The circularized microRNA sponges withstand enzymatic degradation and are completely resistant to microRNA-mediated degradation. They are more effective than typical linear microRNA sponges and microRNA inhibitors in derepressing microRNA targets. They also display superior anti-cancer activities compared to the linear sponges in malignant melanoma cell lines. We have provided an alternative method for circular microRNA sponge production and malignant melanoma treatment.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3′ splice site; 3′SS; 5′ splice site; 5′SS; Circular microRNA sponge; EXO; FITC; Malignant melanoma; PI; PIE; TAP; exonuclease; fluorescein isothiocyanate; miRNAs; microRNA; microRNAs; permutated intron–exon sequences; propidium iodide; tobacco acid pyrophosphatase

Year:  2013        PMID: 24035906     DOI: 10.1016/j.biocel.2013.09.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  30 in total

1.  miR-337 can be a key negative regulator in melanoma.

Authors:  Wanan Xiao; Enyang Yao; Wei Zheng; Feng Tian; Lijie Tian
Journal:  Cancer Biol Ther       Date:  2017-05-12       Impact factor: 4.742

Review 2.  The emerging role of miRNAs in inflammatory bowel disease: a review.

Authors:  Christopher G Chapman; Joel Pekow
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

Review 3.  Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives.

Authors:  Dong-Liang Cheng; Yuan-Yuan Xiang; Li-juan Ji; Xiao-Jie Lu
Journal:  Tumour Biol       Date:  2015-01-22

4.  Detecting and characterizing circular RNAs.

Authors:  William R Jeck; Norman E Sharpless
Journal:  Nat Biotechnol       Date:  2014-05       Impact factor: 54.908

Review 5.  Competing endogenous RNA in cancer: a new pattern of gene expression regulation.

Authors:  Jingjing Qu; Min Li; Wen Zhong; Chengping Hu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 6.  Circular RNAs as potential biomarkers for cancer diagnosis and therapy.

Authors:  Fengling Wang; Adil J Nazarali; Shaoping Ji
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

7.  Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.

Authors:  Ana L Teixeira; Marta Ferreira; Joana Silva; Mónica Gomes; Francisca Dias; Juliana I Santos; Joaquina Maurício; Francisco Lobo; Rui Medeiros
Journal:  Tumour Biol       Date:  2013-12-31

8.  Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.

Authors:  Gang Deng; Ronghao Wang; Yin Sun; Chi-Ping Huang; Shuyuan Yeh; Bosen You; Changyong Feng; Gonghui Li; Shenglin Ma; Chawnshang Chang
Journal:  Cell Death Differ       Date:  2021-06-14       Impact factor: 15.828

Review 9.  Role of MicroRNAs-221/222 in Digestive Systems.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki
Journal:  J Clin Med       Date:  2015-08-06       Impact factor: 4.241

10.  Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression.

Authors:  Tian Xia; Shengcan Chen; Zhen Jiang; Yongfu Shao; Xiaoming Jiang; Peifei Li; Bingxiu Xiao; Junming Guo
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.